Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review

Identifier:  imarina:9454150

Handle: https://hdl.handle.net/20.500.11797/imarina9454150

Authors:  Pais, Marco Marotta; Zaragoza, Rafael; Martin-Loeches, Ignacio; Gomez-Bertomeu, Frederic F; Rodriguez, Alejandro

Abstract:
Intra-abdominal candidiasis (IAC), with or without candidemia, is a common condition in patients in intensive care units (ICUs). Early diagnosis of IAC remains a challenge for clinicians despite new biomarkers. Early and appropriate antifungal treatment, which is associated with better clinical outcomes, is negatively affected by the increased isolation of non-albicans Candida strains that are resistant to the commonly used azoles and echinocandins. Based on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the different treatment options, liposomal amphotericin B, rezafungin or high doses of anidulafungin appear to be the most appropriate first-line options for complicated IAC in ICUs.